TD Cowen Maintains REE Automotive Ltd - Outperform ... - Nasdaq
CBI Stock | 34.90 0.60 1.69% |
About 61% of Clal Biotechnology's investor base is looking to short. The analysis of current outlook of investing in Clal Biotechnology Industries suggests that many traders are alarmed regarding Clal Biotechnology's prospects. The current market sentiment, together with Clal Biotechnology's historical and current headlines, can help investors time the market. In addition, many technical investors use Clal Biotechnology stock news signals to limit their universe of possible portfolio assets.
Clal |
TD Cowen Maintains REE Automotive Ltd - Outperform ... Nasdaq
Read at news.google.com
Clal Biotechnology Fundamental Analysis
We analyze Clal Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clal Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clal Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Clal Biotechnology is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Clal Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Clal Biotechnology stock to make a market-neutral strategy. Peer analysis of Clal Biotechnology could also be used in its relative valuation, which is a method of valuing Clal Biotechnology by comparing valuation metrics with similar companies.
Peers
Clal Biotechnology Related Equities
CGEN | Compugen | 7.06 | ||||
EVGN | Evogene | 3.59 | ||||
BEZQ | Bezeq Israeli | 1.65 | ||||
KMDA | Kamada | 1.80 | ||||
BLRX | BioLine RX | 4.55 |
Complementary Tools for Clal Stock analysis
When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |